🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Placebo (ziltivekimab), ziltivekimab

    NovoThirteen

    Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

    phase 3 small molecule active

    1 trial

  2. Placebo (ziltivekimab), ziltivekimab

    NovoThirteen

    Acute myocardial infarction

    phase 3 small molecule active

    1 trial

  3. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  4. Placebo - Film coated tablet for oral use, atrasentan

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  5. Placebo - Staloral birch, oromucosal solution, STALORAL Birke 10 IR/ml und 300 IR/ml, Lösung zur Anwendung in der Mundhöhle, STALORAL Birke 300 IR/ml, Lösung zur Anwendung in der Mundhöhle

    Allergen

    Birch Pollen-induced Allergic Rhinoconjunctivitis

    phase 3 small molecule active

    1 trial

  6. Placebo - film-coated tablets, Lynparza 100 mg film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer

    phase 3 small molecule active

    1 trial

  7. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023 200 mg), IPTACOPAN

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 3 small molecule active

    1 trial

  8. Placebo 0 mg hard gelatin capsule size 0, (placebo to LNP023), IPTACOPAN

    Novartis Pharmaceuticals

    generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  9. Placebo 0 mg hard gelatin capsule size 1, (placebo to lnp023 100 mg), Placebo 0 mg hard gelatin capsule size 0, (placebo to lnp023 200 mg), IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    complement 3 glomerulopathy

    phase 3 small molecule active

    1 trial

  10. Placebo 0 mg/1 mL Solution for infusion/injection, VAY736

    Novartis Pharmaceuticals

    Autoimmune hepatitis

    phase 3 small molecule active

    1 trial

  11. Placebo 15mg Tablets, Placebo 6mg tablets, venglustat GZ402671 - SAR402671, venglustat GZ402671 - SAR402671

    Sanofi-aventis Healthcare Pty Ltd

    Fabry Disease

    phase 3 small molecule active

    1 trial

  12. Placebo ADCETRIS ( NaCl 0.9% 100 mL - Injection IV ), ADCETRIS 50 mg powder for concentrate for solution for infusion.

    Pari Pharma GmbH

    rare disease

    phase 3 small molecule active

    1 trial

  13. Placebo Colchicine 0.5 mg tablets, Colchicine Tiofarma 0,5 mg, tabletten

    Disc Medicine

    Aortic Valve Calcification, Inflammation, Calcification, Aortic Valve Disease, Cardiovascular Diseases, Aortic Valve Stenosis

    phase 3 small molecule active

    1 trial

  14. Placebo Film-coated tablet, JNJ-42847922

    Janssen-Cilag International N.V.

    Major Depressive Disorder with Insomnia Symptoms

    phase 3 small molecule active

    1 trial

  15. Placebo IRBESARTAN EG 150 mg, Irbesartan EG 150 mg comprimés pelliculés

    Pari Pharma GmbH

    Acute kidney injury

    phase 3 small molecule active

    1 trial

  16. Placebo Injection, Retatrutide, Retatrutide, Retatrutide, Retatrutide, Retatrutide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  17. Placebo JNJ-78278343, Placebo JNJ-78278343, JNJ-78278343, JNJ-78278343

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  18. Placebo MDPI

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    3 trials

  19. Placebo Mannitol 100mg pfi, ACEPURIN, poeder voor infusievloeistof 1g/100 ml

    Disc Medicine

    Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.

    phase 3 small molecule active

    1 trial

  20. Placebo Matching Mitapivat

    Agios Netherlands B.V.

    Non-Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  21. Placebo Matching Mitapivat

    Agios Netherlands B.V.

    Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  22. Placebo Nasal Aerosol

    Teva Pharma GmbH

    Perennial Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  23. Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  24. Placebo Ocrevus, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE , METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Ocrevus 300 mg concentrate for solution for infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Dormutil N, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Primary progressive multiple sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources